Experienced in Hypoplastic Left Heart Syndrome (HLHS)

Dr. Nabil Dib

Interventional Cardiology | Cardiology
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
Accepting New Patients
Experienced in Hypoplastic Left Heart Syndrome (HLHS)
Sjhmc Physician Services
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, 
Phoenix, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nabil Dib is an Interventional Cardiologist and a Cardiologist in Phoenix, Arizona. Dr. Dib is rated as an Experienced provider by MediFind in the treatment of Hypoplastic Left Heart Syndrome (HLHS). His top areas of expertise are Coronary Heart Disease, Atherosclerosis, Double Discordia, Heart Transplant, and Atherectomy. Dr. Dib is currently accepting new patients.

His clinical research consists of co-authoring 48 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hypoplastic Left Heart Syndrome (HLHS).

Specialties
Interventional Cardiology
Cardiology
Licenses
Internal Medicine in AZ
Hospital Affiliations
Mercy Gilbert Medical Center
St. Joseph's Hospital And Medical Center
Chandler Regional Medical Center
Languages Spoken
English
Arabic
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

SJHMC PHYSICIAN SERVICES
500 W Thomas Rd, 680 Dhmg St Joseph's Pelvi, Phoenix, AZ 85013

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure
RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2025
Intervention Type: Other, Device
Study Phase: Not Applicable
OSB Lead-AMPLATZER PFO Occluder New Enrollment PAS
OSB Lead-AMPLATZER PFO Occluder New Enrollment PAS
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2025
Intervention Type: Device
Study Phase: Not Applicable
Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial
Multicenter Randomized Assessment of the Firehawk™ Rapamycin TARGET Eluting Cobalt Chromium Coronary Stent System - North American Trial
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2024
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
A Phase 3, Multinational, Randomized, Placebo-controlled Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Other, Drug
Study Drug: ARRY-371797 (PF-07265803)
Study Phase: Phase 3
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions
Enrollment Status: Completed
Publish Date: October 30, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.
A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.
Enrollment Status: Completed
Publish Date: October 11, 2023
Intervention Type: Device
Study Phase: Not Applicable
Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
Mesenchymal Stromal Cells for the Treatment of Moderate to Severe COVID-19 Acute Respiratory Distress Syndrome
Enrollment Status: Terminated
Publish Date: April 25, 2022
Intervention Type: Biological, Drug
Study Drug: Remestemcel-L
Study Phase: Phase 3
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Human Recombinant Fibroblast Growth Factor-1 (FGF-1), for the Treatment of Subjects With Severe Coronary Heart Disease, a Placebo Controlled, Double-blind, Dose-varying Study
Enrollment Status: Unknown
Publish Date: November 01, 2019
Intervention Type: Combination product
Study Drug: Human Recombinant Fibroblast Growth Factor-1
Study Phase: Phase 2
View 7 Less Clinical Trials

48 Total Publications

From the Hazards of Death to the Hazards of Indication Creep for TAVR.
From the Hazards of Death to the Hazards of Indication Creep for TAVR.
Journal: Journal of the American College of Cardiology
Published: May 19, 2025
Similar Doctors
Advanced in Hypoplastic Left Heart Syndrome (HLHS)
Dr. John H. Stock
Pediatric Cardiology | Cardiology
Advanced in Hypoplastic Left Heart Syndrome (HLHS)
Dr. John H. Stock
Pediatric Cardiology | Cardiology
7505 S Mcclintock Dr, Suite 103, 
Tempe, AZ 
 (13.3 miles away)
480-755-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

John Stock is a Pediatric Cardiologist and a Cardiologist in Tempe, Arizona. Dr. Stock is rated as an Advanced provider by MediFind in the treatment of Hypoplastic Left Heart Syndrome (HLHS). His top areas of expertise are Ventricular Septal Defects, Pulmonary Supravalvular Stenosis, Pulmonary Valve Stenosis, and Heart Murmurs. Dr. Stock is currently accepting new patients.

Advanced in Hypoplastic Left Heart Syndrome (HLHS)
Dr. Deepti Bhat
Pediatric Cardiology | Pediatrics | Cardiology
Advanced in Hypoplastic Left Heart Syndrome (HLHS)
Dr. Deepti Bhat
Pediatric Cardiology | Pediatrics | Cardiology

Phoenix Children's Hospital

1919 E Thomas Rd, 
Phoenix, AZ 
 (2.3 miles away)
602-933-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Deepti Bhat is a Pediatric Cardiologist and a Pediatrics provider in Phoenix, Arizona. Dr. Bhat is rated as an Advanced provider by MediFind in the treatment of Hypoplastic Left Heart Syndrome (HLHS). Her top areas of expertise are Double Inlet Left Ventricle, Pulmonary Atresia with Intact Ventricular Septum, Right Ventricle Hypoplasia, Transposition of the Great Arteries, and Angioplasty.

Advanced in Hypoplastic Left Heart Syndrome (HLHS)
Dr. Todd Nowlen
Pediatric Cardiology | Cardiology | Pediatrics
Advanced in Hypoplastic Left Heart Syndrome (HLHS)
Dr. Todd Nowlen
Pediatric Cardiology | Cardiology | Pediatrics

Phoenix Children's Hospital

1919 E Thomas Rd, 
Phoenix, AZ 
 (2.3 miles away)
602-933-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Todd Nowlen is a Pediatric Cardiologist and a Cardiologist in Phoenix, Arizona. Dr. Nowlen is rated as an Advanced provider by MediFind in the treatment of Hypoplastic Left Heart Syndrome (HLHS). His top areas of expertise are Kawasaki Disease, Multisystem Inflammatory Syndrome in Children (MIS-C), Coronary Artery Fistula, and Ventricular Septal Defects.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dib's expertise for a condition
ConditionClose
      View All 8 Advanced Conditions
      View All 45 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile